Tonix Pharmaceuticals' Tonmya Becomes First New Fibromyalgia Drug in Over 15 Years, Transforming the Chronic Pain Treatment Landscape
核心洞察
Tonix Pharmaceuticals (搜索) received FDA approval for Tonmya (搜索) (cyclobenzaprine HCl sublingual tablets) in August 2025, the first new fibromyalgia (搜索) medication in more than 15 years.
The non-opioid, once-daily bedtime therapy is now available by prescription across the U.S., offering renewed hope for nearly 10 million American adults living with fibromyalgia (搜索).
The global pain management drugs market was valued at USD 74.02 billion in 2025 and is projected to reach USD 117.18 billion by 2034, driven by demand for safer non-opioid alternatives.
The chronic pain (搜索) treatment landscape has entered a new era with the U.S. Food and Drug Administration's approval of Tonmya (搜索) (cyclobenzaprine HCl sublingual tablets), developed by Tonix Pharmaceuticals (搜索) Holding Corp. Announced in August 2025, the approval marks the first new medication for fibromyalgia (搜索) introduced in more than 15 years. The drug is now available by prescription at pharmacies across the United States, providing a long-awaited non-opioid option for nearly 10 million American adults living with this challenging condition.
Tonmya (搜索) is a first-in-class, non-opioid analgesic taken once daily at bedtime. Its sublingual formulation represents a novel approach to fibromyalgia (搜索) management, a chronic pain (搜索) condition that has seen little therapeutic innovation for over a decade. The launch, which occurred in November 2025, positions Tonix Pharmaceuticals (搜索) as a key player in the rapidly evolving chronic pain market.
The Opioid Crisis and the Urgent Need for Alternatives
The approval of Tonmya (搜索) arrives against the backdrop of an ongoing opioid crisis that continues to shape regulatory and clinical priorities. In September 2025, FDA Commissioner Marty Makary, MD, MPH, underscored the urgency of expanding non-opioid treatment options, noting that physicians urgently need more alternatives to opioids for managing chronic pain (搜索). Although opioid prescribing has declined in recent years, the FDA reported that approximately one in five U.S. adults with chronic pain continues to receive opioid prescriptions due to a lack of effective alternatives.
The Centers for Disease Control and Prevention (CDC) estimates that 8% to 12% of patients on prolonged opioid therapy experience misuse, further intensifying the need for safer therapeutic options. In July 2025, the FDA required major safety labeling changes for all opioid pain medications to more clearly highlight risks linked with long-term use, including misuse, addiction, and fatal or non-fatal overdose.
Market Growth and the Shift Toward Non-Opioid Therapies
The global pain management drugs market was valued at USD 74.02 billion in 2025 and is projected to grow to USD 117.18 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 5.29% during the forecast period, according to Fortune Business Insights. The chronic pain (搜索) segment dominated the market in 2025, driven by conditions such as arthritis, neuropathic pain, chronic back pain, migraine, fibromyalgia (搜索), and cancer-related pain, all of which often require long-term or repeated treatment.
North America held the dominant market share in 2024, valued at USD 33.70 billion, with the U.S. market alone estimated to reach approximately USD 33.77 billion in 2026, accounting for roughly 43.53% of global revenue. The fibromyalgia (搜索) segment is projected to grow at a CAGR of 7.93% during the forecast period, reflecting the significant unmet need that Tonmya (搜索) aims to address.
A Pipeline-Driven Transformation
The chronic pain (搜索) market is expected to surge due to increasing prevalence and awareness, with multiple pipeline products poised to revolutionize treatment dynamics, according to DelveInsight's Chronic Pain Market Forecast. Key companies advancing therapies include Seikagaku Corporation with JOYCLU (diclofenac etalhyaluronate sodium), Pacira BioSciences (搜索) with ZILRETTA (triamcinolone acetonide extended-release injectable suspension), and Paradigm Biopharmaceuticals with ZILOSUL (pentosan polysulfate sodium).
In October 2025, Pacira BioSciences (搜索) announced new real-world evidence for EXPAREL (bupivacaine liposome injectable suspension), evaluating its clinical and economic benefits in non-opioid postsurgical pain management as part of opioid-sparing strategies. Meanwhile, in January 2025, Vertex Pharmaceuticals received FDA approval for JOURNAVX (suzetrigine), a non-opioid oral medicine for adults with moderate-to-severe acute pain, marking another significant milestone in the shift away from opioid dependence.
Epidemiology and Patient Impact
In 2023, the United States recorded the highest prevalence of chronic pain (搜索) cases among the seven major markets (7MM). Approximately 70% of chronic pain cases in the U.S. were classified as moderate to severe in severity, with prevalence increasing with age and the highest rates observed in individuals aged 45 to 64 years. Among the EU4 and the UK, the United Kingdom had the highest prevalence, accounting for approximately 30% of cases.
The introduction of Tonmya (搜索) directly addresses a condition—fibromyalgia (搜索)—that has persistent unmet treatment needs. As a non-opioid, once-daily sublingual therapy, it aligns with the broader industry trend toward multimodal, opioid-sparing pain management approaches that target different pain pathways while reducing dependence on high-dose opioids.
Industry Consolidation and Future Directions
The competitive landscape continues to evolve through strategic acquisitions and product launches. In May 2025, Eli Lilly and Company acquired SiteOne Therapeutics, Inc., gaining STC-004, a Phase 2-ready Nav1.8 inhibitor being studied for chronic pain (搜索), representing a potential next-generation non-opioid treatment. In June 2026, AbbVie received European Commission approval for AQUIPTA (atogepant) for acute migraine treatment, while Amneal Pharmaceuticals launched BREKIYA, the first ready-to-use DHE autoinjector for migraine and cluster headaches, in October 2025.
The convergence of regulatory pressure to reduce opioid use, a robust pipeline of non-opioid therapies, and growing market demand for safer chronic pain (搜索) management positions the sector for significant transformation through 2034. Tonmya (搜索)'s approval and launch represent both a clinical milestone for fibromyalgia (搜索) patients and a signal of the pharmaceutical industry's accelerating pivot toward targeted, non-addictive pain therapies.